US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
AbstractThe report covers forecast and analysis for the electronic drug delivery systems market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the electronic drug delivery systems market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the electronic drug delivery systems market on a global as well as regional level. According to the report, global demand for the electronic drug delivery systems market was valued at approximately USD 7.2 Billion in 2018 and is expected to generate revenue of around USD 13.3 Billion by end of 2025, growing at a CAGR of around 9.2% between 2019 and 2025. In order to give the users of this report a comprehensive view on the electronic drug delivery systems market, we have included a competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein the product and services segment is benchmarked based on their market size, growth rate, and general attractiveness. The report provides company market share analysis in order to give a broader overview of the key players in the electronic drug delivery systems market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the electronic drug delivery systems market on a global and regional basis. Electronic drug delivery systems (EDDS) are an important part of the innovation in the field of drug delivery systems. EDDS are interactive, portable, wirelessly connected, and enable patient-supervised therapy. These factors play a vital role in decreasing overall healthcare expenditures. EDDS has immense potential in the field of targeted drug delivery. By delivering optimum concentration of doses to specific body parts, targeted drug delivery helps in reducing the dosage frequency of potentially harmful drugs. Factors such as growing incidence of target ailments, major advancements in the design of EDDS, increasing prevalence of chronic ailments, and positive reimbursement situation in developed regions will act as major driving factors in the growth of the global electronic drug delivery systems market. Application of EDDS in targeted drug delivery and increasing research and development initiatives will act as an opportunity for the market players in the electronic drug delivery systems market. Nonetheless, the high cost of electronic drug delivery systems, the need for maintenance, and lack of awareness in low-income countries will restrict the growth of the global electronic drug delivery systems market. The global electronic drug delivery systems market has been split into type, indication, and region. Based on type, the electronic drug delivery systems market has been segmented into electronic autoinjectors, electronic wearable infusion pumps, electronic inhalers, and electronic injection pens. The electronic wearable infusion pumps segment accounted for the highest market share in 2018 due to increasing diabetes incidence and the growing accessibility of commercial infusion pumps. The indication segment has been segmented into multiple sclerosis, diabetes, asthma & COPD, cardiovascular disease, and other indications. The diabetes segment accounted for the highest market share in 2018 due to an increase in the number of diabetes cases around the world and the launch of new products. North America will be the leading region during the forecast period. Quick uptake of new technologies, high prevalence of target disorders, easy availability of electronic drug delivery devices, and presence of leading market players will boost the market growth in this region. Europe will be the second-largest market. The major reasons are existence of skilled physicians, growth in awareness concerning the use of electronic drug delivery devices, high diabetes incidence, and favorable reimbursement setup. The Asia Pacific will proliferate at a speedy rate over the forecast period due to fast technological improvements in the healthcare sector and swelling cases of asthma and other respiratory ailments. Latin America market will progress at a noteworthy rate during the estimated period. The Middle Eastern and African countries are expected to experience noticeable growth in the projected time-frame. The report also includes detailed profiles of key players such as Medtronic plc, Insulet Corporation, Merck Group, Bayer AG, Novo Nordisk, AstraZeneca, United Therapeutics Corporation, Amgen, and Tandem Diabetes Care among others.
This report segments the Global Electronic Drug Delivery Systems Market as follows:
Global Electronic Drug Delivery Systems Market: By Type
- Electronic Autoinjectors
- Electronic Wearable Infusion Pumps
- Electronic Inhalers
- Electronic Injection Pens
Global Electronic Drug Delivery Systems Market: By Indication
- Multiple Sclerosis
- Asthma & COPD
- Cardiovascular Disease
- Other Indications
Global Electronic Drug Delivery Systems Market: By Region
In September 2020, GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ˜FF/UMEC/VI) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate / umeclidinium / vilanterol 200/62.5/25mcg. The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US. The approval is an important advance for patients as it allows them to benefit from triple therapy by using one inhaler, once-a-day. Trelegys approval for the maintenance treatment of asthma in patients aged 18 years and older introduces a new paradigm for managing the approximately 30% of adult asthma patients who still experience symptoms despite being adherent to inhaled corticosteroids/ long-acting beta-agonist (ICS/LABA) combination therapy. In the US there are almost 20 million adults living with asthma and many of those continue to live with and adapt their lives around ongoing symptoms. FF/UMEC/VI is a combination of three molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSKs Ellipta dry powder inhaler.
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- Middle East & Africa
Table of Contents Request Table Of Content Click To Request Sample Chapter 1. Preface 1.1. Report Description and Scope 1.2. Research Scope 1.3. Research Methodulogy 1.3.1. Market Research Process 1.3.2. Market Research Methodulogy Chapter 2. Executive Summary 2.1. Electronic Drug Delivery Systems Market, 2016–2025 (USD Billion) 2.2. Electronic Drug Delivery Systems Market: Snapshot Chapter 3. | read more...